SequelSEC

GENELUX Corp GNLX

Pharmaceutical Preparations · CIK 0001231457 · Fiscal year ends 1231

Revenue
$8.00K
Fiscal year ended 2024-12-31
Operating income
-$31.70M
Fiscal year ended 2024-12-31
Free cash flow
-$21.61M
Fiscal year ended 2024-12-31

Valuation, from the filing

Public float$89.10MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$1.99Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue11137.5×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity7.7×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue13725.0%100th
R&D / revenue248137.5%100th
FCF margin-329575.0%1th
Net margin-401812.5%1th
Operating margin-415175.0%1th
SBC / revenue73387.5%99th
Current ratio2.43x33th
Revenue YoY growth0.0%43th

GENELUX Corp (GNLX) reported revenue of $8.00K and net income of -$29.87M for the fiscal year ended 2024-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from GENELUX Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

GENELUX Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-31
Revenue$8.00K
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$31.70M
Net income-$29.87M
Research & development$19.00M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$12.71M
Selling & marketingUnavailable

Balance

GENELUX Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-31
Cash & equivalents$8.56M
Total assets$34.72M
Current assets$31.55M
Total liabilities$8.44M
Current liabilities$6.90M
Total equity incl. NCI$26.27M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

GENELUX Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-31
Operating cash flow-$21.23M
Capital expenditures$381.00K
Investing cash flow-$8.13M
Financing cash flow$28.51M
Net change in cash-$853.00K
Stock-based compensation$5.74M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

GENELUX Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-31
Free cash flow-$21.61M
Gross marginUnavailable
Operating margin-396200.0%
FCF margin-270112.5%
SBC / revenue71725.0%
Current ratio4.57x
Revenue YoY growth-95.3%
Net margin-373362.5%
R&D / revenue237475.0%
CapEx / revenue4762.5%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open GNLX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-19View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.